F44-A13

Overview

F44-A13 is an orally active and highly selective farnesoid X receptor ( FXR ) antagonist with an IC 50 value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol , triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > FXR | Products > Signaling Pathways > Cytochrome P450 | Products > Signaling Pathways > RAR/RXR | Products > Signaling Pathways > PPAR | Products > Signaling Pathways > ROR

Product Information

• Catalog No.: HY-163436
• CAS No.: 1338190-14-9
• Molecular Formula: C28H40N4O5S
• Molecular Weight: 544.71
• Purity: 96.73%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (4.59 mM); Clear solution
• Availability: In-stock

Source

Original product source